Showing 1 - 8 results of 8 for search 'Neal D. Shore', query time: 0.04s Refine Results
  1. 1
    Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36

    Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs... by Neal D. Shore

    Published 2022-12-01
    Get full text
    Article
  2. 2
    Clinical use of nadofaragene firadenovec-vncg

    Clinical use of nadofaragene firadenovec-vncg by Badrinath R. Konety, Neal D. Shore, Grannum R. Sant

    Published 2024-09-01
    Get full text
    Article
  3. 3
    Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia

    Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia by Bilal Chughtai, Sirikan Rojanasarot, Kurt Neeser, Dmitry Gultyaev, Stacey L. Amorosi, Neal D. Shore

    Published 2021-05-01
    Get full text
    Article
  4. 4
    Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists

    Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists by Mohamad Moussa, Mohamad Abou Chakra, Neal D. Shore, Athanasios Papatsoris, Yasser Farahat, Michael A. O’Donnell

    Published 2024-03-01
    Get full text
    Article
  5. 5
    Mechanism of action of nadofaragene firadenovec-vncg

    Mechanism of action of nadofaragene firadenovec-vncg by Vikram M. Narayan, Joshua J. Meeks, Jørn S. Jakobsen, Neal D. Shore, Grannum R. Sant, Badrinath R. Konety

    Published 2024-03-01
    Get full text
    Article
  6. 6
    A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design

    A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local th... by Ugo De Giorgi, Martin Gleave, Brad Rosbrook, Stephen J Freedland, Qi Shen, Jennifer Sugg, Gabriel P Haas, Neal D Shore

    Published 2021-08-01
    Get full text
    Article
  7. 7
    Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerResearch in context

    Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerR... by Celestia S. Higano, Daniel J. George, Neal D. Shore, Oliver Sartor, Kurt Miller, Peter S. Conti, Cora N. Sternberg, Fred Saad, Juan Pablo Sade, Joaquim Bellmunt, Matthew R. Smith, Kumari Chandrawansa, Per Sandström, Frank Verholen, Bertrand Tombal

    Published 2023-06-01
    Get full text
    Article
  8. 8
    The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

    The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma by Daniel P. Petrylak, Lawrence Fong, Charles G. Drake, Mark N. Stein, Douglas G. McNeel, Ravi A. Madan, James L. Gulley, Neil H. Bander, Tomasz M. Beer, Stacey Harrelson, Philip W. Kantoff, William K. Oh, David J. Peace, Hank Porterfield, Oliver Sartor, Neal D. Shore, Susan F. Slovin, Johannes Vieweg

    Published 2016-12-01
    Get full text
    Article

Search Tools: